Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bevacizumab + XELOX in advanced colorectal cancer
2005-001012-41Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, capecitabine and oxaliplatin in colorectal cancer (CRC), sponsored by Roche. Primary endpoints: Overall response rate, Complete remission and 1 more. Started Feb 2007; status: completed.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-001012-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001012-41.